Newsroom

Sorted by: Latest

-

Invivoscribe® lance LeukoStrat®   KMT2A + MRD Assay afin de faire progresser les tests de leucémie à haute sensibilité dans les essais cliniques et la prise en charge des patients dans le monde entier

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, leader dans le domaine de la médecine de précision et des tests de maladie résiduelle mesurable (MRD), a annoncé aujourd’hui l’ajout du test et du logiciel LeukoStrat® KMT2A + MRD à son portefeuille de produits oncologiques de pointe. Ce test utilise la PCR numérique (dPCR) pour faciliter le dépistage et la surveillance longitudinale précise de la MRD pour les réarrangements KMT2A chez les patients atteints de leucémie myéloïde aiguë (LMA). Ce test quan...
-

Stephen Riddell and Gallatin Point Launch DS2 Capital, a CLO-Focused Credit Investment Firm

CHARLOTTE, N.C. & GREENWICH, Conn.--(BUSINESS WIRE)--Stephen Riddell and Gallatin Point Capital LLC (“Gallatin Point”) today announced the launch of DS2 Capital (“DS2”), a credit investment firm specializing in actively managed collateralized loan obligation (“CLO”) strategies. Riddell, a veteran credit investor and former Chief Investment Officer of one of the largest U.S. CLO managers, will serve as Chief Executive Officer and Chief Investment Officer of the firm. DS2 launches with significan...
-

Third Century Bancorp Releases Earnings for the Quarter and Year Ended December 31, 2025

FRANKLIN, Ind.--(BUSINESS WIRE)--(OTCID: TDCB) - Third Century Bancorp (“Company”), the holding company for Mutual Savings Bank (“Bank”), announced it recorded unaudited net income of $550,000 for the quarter ended December 31, 2025, or $0.47 per basic and diluted share, compared to net income of $492,000 for the quarter ended December 31, 2024, or $0.42 per basic and diluted share. In addition, the Company recorded net income of $1,871,000 for the year ended December 31, 2025, or $1.61 per bas...
-

Cencosud Closes 2025 With 70.4% Increase in Net Income, Sales Growth, and Improved Profitability

SANTIAGO, Chile--(BUSINESS WIRE)--Cencosud closed 2025 with solid financial performance, highlighting an increase in accumulated Net Income, while continuing to advance consistently in the consolidation of its Retail Ecosystem and its profitable growth strategy across Latin America and the United States. During fiscal year 2025, the Company recorded a 70.4% increase in accumulated Net Income, reaching CLP 398,119 million (USD 419 million). Full-year revenues amounted to CLP 16,595 billion (USD...
-

martinwolf Advises Step Up Consulting on its Acquisition by Armanino

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--martinwolf, a leading lower middle market M&A advisor exclusively focused on IT, announced today that it has advised Step Up Consulting, a UKG Ready focused implementations and support partner, on its acquisition by Armanino, one of the 20 largest accounting and business consulting firms in the U.S. “martinwolf’s knowledge, persuasive leadership, and candid guidance gave us the confidence we needed to pursue the right outcome,” said Praneet Panga, Chief F...
-

Riassunto: Invivoscribe® presenta il test LeukoStrat® KMT2A + MRD per favorire i progressi dei test ad alta sensibilità per la leucemia nelle sperimentazioni cliniche e nella gestione dei pazienti a livello globale

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, azienda leader nell'ambito della medicina di precisione e dei test della malattia residua misurabile (MRD), ha annunciato oggi l'aggiunta del test e software LeukoStrat® KMT2A + MRD al proprio portafoglio oncologico leader del settore. Il test sfrutta la tecnologia digital PCR (dPCR) a sostegno sia dello screening che del monitoraggio longitudinale accurato della MRD per i riarrangiamenti del gene KMT2A nei soggetti affetti da leucemia mieloide acuta (A...
-

Samenvatting: Invivoscribe®  lanceert LeukoStrat®   KMT2A + MRD-test om wereldwijd hoogwaardige leukemietests in klinische onderzoeken en patiëntenbeheer te bevorderen

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, toonaangevend op het gebied van precisiegeneeskunde en meetbare restziekte (MRD)-tests, kondigde vandaag aan dat het de LeukoStrat® KMT2A + MRD-test en -software aan zijn toonaangevende oncologieportfolio heeft toegevoegd. De test maakt gebruik van digitale PCR (dPCR) om zowel screening als nauwkeurige longitudinale MRD-monitoring van KMT2A-herschikkingen bij patiënten met acute myeloïde leukemie (AML) te ondersteunen. Deze kwantitatieve test is momente...
-

Pramata Enhances Claude Cowork Legal Plugin with Essential Contract Intelligence, Transforming How Enterprises Negotiate and Manage Contracts

SAN FRANCISCO--(BUSINESS WIRE)--Pramata, the leader in contract intelligence and commercial relationship context, today announced its extension with Anthropic’s Claude Cowork Legal plugin, bringing unprecedented contract intelligence capabilities to enterprise users. This integration enables Fortune 500 legal, finance, and operations teams to access comprehensive commercial relationship context directly within Claude's AI-powered interface, transforming how organizations negotiate, review, and...
-

インビボスクライブ®、世界中の臨床試験および患者の管理における高感度白血病検査を推進すべく、LeukoStrat®   KMT2A+MRDアッセイを発売

サンディエゴ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 精密医療および測定可能残存病変(MRD)検査のリーダーであるインビボスクライブは、業界をリードするがん治療製品ポートフォリオにLeukoStrat® KMT2A+MRDアッセイおよびソフトウェアが今回新たに加わったことを発表しました。 本アッセイはデジタルPCR(dPCR)技術を活用し、急性骨髄性白血病(AML)患者におけるKMT2A再構成のスクリーニングおよび精密かつ長期的なMRDモニタリングを支援します。この定量検査は現在、臨床試験における研究用途、そして世界中のお客様が購入することができるスタンドアロンキットとして提供されており、まもなく世界各国の地域別LabPMM®ラボにおけるサービスとしても利用可能となります。 本アッセイは、AMLに関連する主要なKMT2A再構成 を検出可能であり、これらはAMLにおけるKMT2A融合パートナーの大部分を占め1、メニン阻害剤の臨床開発プログラムで最も標的とされるものとなります。今年の後半には、急性リンパ性白血病(ALL)で頻繁に認められる4つのKMT2A再構成がアッ...
-

Insurance Funding for Buffalo Catholic Diocese Sex Abuse Survivors Exceeds $160 Million

BUFFALO, N.Y.--(BUSINESS WIRE)--The Catholic Diocese of Buffalo is nearing completion of settling claims for more than 900 survivors of sexual abuse by diocesan priests and other leaders in cases dating back decades. As currently projected, the financial settlement for victims is approaching $315 million, with a significant portion of that funding – nearly $165 million – being supplied by insurers of the diocese. Key to the process has been the involvement of the Burns Bair law firm, whose atto...